Last $0.27 USD
Change Today 0.00 / 0.00%
Volume 12.5K
INSV On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

insite vision inc (INSV) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/14/14 - $0.35
52 Week Low
06/3/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSITE VISION INC (INSV)

insite vision inc (INSV) Related Bloomberg News

View More Bloomberg News

insite vision inc (INSV) Related Businessweek News

No Related Businessweek News Found

insite vision inc (INSV) Details

InSite Vision Incorporated, an ophthalmic product development company, develops ophthalmic pharmaceutical products to address unmet eye care needs in the United States. It is developing products based on its proprietary DuraSite drug delivery technology. The company’s lead products comprise AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. Its products also include ISV-101, a formulation with a low concentration of bromfenac for the treatment of dry eye disease. In addition, the company is involved in preparing a new drug application for the commercial approval of BromSite by the U.S. Food & Drug Administration for the prevention of pain and inflammation associated with ocular surgery; and advancing AzaSite Plus and DexaSite through Phase III clinical studies for the treatment of eye infections. Further, it has a pipeline of earlier-stage product candidates based on its platform technologies. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn Pharmaceuticals; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.

31 Employees
Last Reported Date: 03/31/14
Founded in 1986

insite vision inc (INSV) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $380.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $264.2K
Vice President of Operations and Quality
Total Annual Compensation: $236.3K
Chief Medical Officer, Vice President of Clin...
Total Annual Compensation: $347.3K
Vice President of Development and Secretary
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

insite vision inc (INSV) Key Developments

Insite Vision Incorporated Approves to Adopt Amendments to the Restated Certificate of Incorporation

InSite Vision Incorporated announced that the proposal to adopt an amendment to Article 4 of the company's restated certificate of incorporation to increase the number of authorized shares has not been approved and the proposal to adopt an amendment to Article 4 of the company's restated certificate of incorporation to effect the contingent reverse stock split has been approved at the Annual General Meeting held on July 16, 2014.

InSite Vision Incorporated - Shareholder/Analyst Call

Annual Meeting of Stockholders

InSite Vision Plans to Submit New Drug Application to FDA for DexaSite(TM) for the Treatment of Blepharitis in Adults

InSite Vision Incorporated announced that it intends to submit a New Drug Application for DexaSite(TM) (dexamethasone 0.1% in DuraSite) as a treatment for blepharitis in adults during 2015, following completion of remaining chemistry and manufacturing work. In the June 16 meeting, the FDA agreed that in light of all of the historical clinical data for dexamethasone, the results of InSite's Phase 3 study of DexaSite could support marketing approval for DexaSite in the indication of blepharitis. In its landmark Phase 3 DOUBle study, DexaSite achieved superiority versus vehicle (p-value = 0.0053) at day 15 (following 14 days of twice-daily dosing) in the clinical symptom of irritation, which was singularly judged and reported by the patient. Another independent instrument employed in this study, the Health Related Quality of Life Questionnaire, which is a patient reported outcome instrument, also supported the irritation results outcome. InSite believes this is the first time a significant improvement in a blepharitis clinical symptom has been achieved in a Phase 3 setting. InSite will meet with key European regulatory authorities in third quarter of 2014 to request this same DexaSite Marketing Authorization Application (MAA) filing path, as well as feedback on the need, if any, for additional AzaSite Plus (dexamethasone 0.1% and azithromycin 1% in DuraSite) data and/or endpoints to support an AzaSite Plus MAA filing in bacterial-related blepharitis. InSite will also continue to discuss AzaSite Plus data and endpoint requirements in bacterial-related blepharitis with the FDA, and InSite has committed to share with the FDA the results of all European blepharitis meetings, including all final meeting minutes, in an effort to harmonize the regulatory approach.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSV:US $0.27 USD 0.00

INSV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $170.06 USD -0.51
Johnson & Johnson $102.11 USD -0.09
Pfizer Inc $30.19 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation INSV Industry Range
Price/Earnings 11.8x
Price/Sales 3.2x
Price/Book NM Not Meaningful
Price/Cash Flow 11.8x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSITE VISION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at